Substrate | Liver | Intestine | ||||
---|---|---|---|---|---|---|
PB | 3-MC | A1254 | PB | 3-MC | A1254 | |
1-Naphthol | 1.5 | 4.3 | 6.5 | 0.8 | 0.6 | 2.1 |
BP-3,6-quinol | 1.8 | 10.4 | 12.9 | 1.1 | 1.3 | 2.1 |
BP-3,6-quinol-monoglucuronide | 2.3 | 38.2 | 72.0 | 1.1 | 1.1 | 2.8 |
Morphine | 4.3 | 1.3 | 3.5 | 1.0 | 0.6 | 1.8 |
4-Hydroxybiphenyl | 3.3 | 1.5 | 3.1 | 0.8 | 0.4 | 1.3 |
Bilirubin | 1.5 | 0.8 | 0.6 | 0.8 | 0.6 | 1.3 |
Fenoterol | 1.1 | 1.0 | 1.2 | 0.8 | 0.8 | 0.9 |
Data given represent the fold induction with respect to control activities before treatment. The mean control activities in rat liver for 1-naphthol, BP-3,6-quinol, BP-3,6-quinol-monoglucuronide, morphine, 4-hydroxybiphenyl, bilirubin, and fenoterol were 39.6, 4.4, 0.20, 5.8, 13.8, 1.4, and 7.2 nmol/min/mg microsomal protein, respectively. These respective intestinal activities were 21.4, 0.7, 0.2, 0.07, 2.4, 0.4, and 6.6 nmol/min/mg microsomal protein. Pretreatment with PB, 3-MC, and A1254 was performed as follows. PB: An initial dose of 100 mg/kg was given once i.p. and was followed up by 0.1% (w/v) in drinking water; animals were sacrificed 4 days after treatment. 3-MC: A dose of 40 mg/kg, dissolved in olive oil, was given once i.p.; animals were sacrificed 4 days after treatment. A1253: A dose of 500 mg/kg, dissolved in olive oil, was given once i.p.; animals were sacrificed 6 days after treatment. Data were adapted from Koster et al. (1986).